Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Merck & Co., Protillion Biosciences ink $510M biobucks data generation partnership using Prot-MaP protein design platform
Licensing deal, AI/ML, drug discovery, biologics, milestone payments - Read more

Everest Medicines, Dimerix sign exclusive licensing deal for DMX-200 in Asia; $10M upfront, $330M milestones
Licensing deal, rare disease, small molecule, nephrology, milestone payments, royalties - Read more

Adaptive Biotechnologies plans split of Pfizer-partnered drug discovery unit from diagnostics business
Restructuring, drug discovery, diagnostics, T-cell therapy, milestone payments - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Spyre Therapeutics' SPY002 meets Ph2 primary endpoint in ulcerative colitis with "indication-leading" anti-TL1A results
Antibody, autoimmune, monoclonal antibody, ulcerative colitis, anti-TL1A, combination therapy - Read more

Edgewise Therapeutics' (EDG-7500) cardiac sarcomere modulator Ph2 data support Ph3 plans for hypertrophic cardiomyopathy
Small molecule, cardiovascular, cardiac sarcomere modulator, hypertrophic cardiomyopathy, cardiac myosin inhibitor - Read more

Intellia Therapeutics' (lonvoguran ziclumeran) achieves 89% attack reduction in Ph3 hereditary angioedema study
Gene therapy, hereditary angioedema, CRISPR, antisense oligonucleotide, single-dose therapy - Read more

Alto Neuroscience's ALTO-207 (pramipexole/ondansetron) bolstered by independent Ph2 data showing anhedonia benefits in major depressive disorder
Small molecule, neurological, dopamine agonist, major depressive disorder, anhedonia, treatment-resistant depression - Read more

Mirum Pharmaceuticals, Incyte's zilurgisertib (ALK2 inhibitor) bolsters FDA approval case for fibrodysplasia ossificans progressiva after Ph2 results
Small molecule, rare disease, fibrodysplasia ossificans progressiva, ALK2 inhibitor, heterotopic ossification - Read more

Takeda's (oveporexton) Ph3 data show improved functioning, cognition, nighttime sleep in narcolepsy type 1
Small molecule, neurological, orexin receptor agonist, narcolepsy, sleep disorder - Read more

CollimateHealth raises €6M ($6.96M) Seed funding, advancing microbeam radiation therapy for cancer treatment
Oncology, radiation therapy, cancer, preclinical - Read more

Eisai secures UK government grant for $65M Hatfield plant expansion, adding Leqembi cold-chain packaging capabilities
Monoclonal antibody, neurological, operational, manufacturing - Read more

Johnson & Johnson invests $1B in Jacksonville, Florida to upgrade Acuvue contact lens production and distribution
Medical devices, vision care, manufacturing, strategic, major transaction - Read more

Recipharm channels multi-million-dollar U.S. manufacturing upgrade to meet surging domestic biologics demand
Biologics manufacturing, oncology, investment, operational, strategic - Read more

Stealth BioTherapeutics rebrands as Mighty Therapeutics following FDA approval of first Barth syndrome therapy
Peptide therapy, rare disease, commercial, regulatory - Read more

Germany drops variable drug discount plans after Boehringer Ingelheim and Eli Lilly withdraw investments
Drug pricing policy, small molecule, financial, strategic, manufacturing - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Elicio Therapeutics' (ELI-002 7P) KRAS-targeting immunotherapy misses Ph2 endpoint in pancreatic cancer, advances to Ph3
Cancer immunotherapy, cancer, vaccine, pancreatic cancer, KRAS mutation, adjuvant therapy - Read more

Amgen loses Harbour Antibodies patent case, ordered to pay $20M+ in damages
Monoclonal antibody, patent litigation, financial, competitive - Read more

Neumora Therapeutics discontinues navacaprant after Phase III failures, cuts 35% of workforce
Small molecule, neurological, cost reduction, operational - Read more

Traws Pharma defers phase 2a flu trial after UK MHRA negative review, risking $20M funding
Small molecule, infectious disease, regulatory, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here